GrippeAllemagneV4, Main, Exploration, bibRecord, 000131

Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.

Identifieur interne : 000131 ( Main/Exploration ); précédent : 000130; suivant : 000132

Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.

Auteurs : Oliver Damm [Allemagne] ; Martin Eichner ; Markus Andreas Rose ; Markus Knuf ; Peter Wutzler ; Johannes Günter Liese ; Hagen Krüger ; Wolfgang Greiner

Source :

The European journal of health economics : HEPAC : health economics in prevention and care [ 1618-7601 ] ; 2015.

RBID : pubmed:24859492

Descripteurs français

KwdFr :
- Administration par voie nasale (MeSH), Adolescent (MeSH), Allemagne (MeSH), Analgésiques (administration et posologie), Analgésiques (économie), Analyse coût-bénéfice (MeSH), Années de vie ajustées sur la qualité (MeSH), Antibactériens (administration et posologie), Antibactériens (économie), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Grippe humaine (prévention et contrôle), Humains (MeSH), Modèles économétriques (MeSH), Otite moyenne (prévention et contrôle), Otite moyenne (économie), Pneumopathie infectieuse (prévention et contrôle), Pneumopathie infectieuse (économie), Santé publique (économie), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (économie), Vaccins atténués (administration et posologie), Vaccins atténués (effets indésirables), Vaccins atténués (économie).
MESH :
- administration et posologie : Analgésiques, Antibactériens, Vaccins antigrippaux, Vaccins atténués.
- effets indésirables : Vaccins antigrippaux, Vaccins atténués.
- prévention et contrôle : Grippe humaine, Otite moyenne, Pneumopathie infectieuse.
- économie : Analgésiques, Antibactériens, Otite moyenne, Pneumopathie infectieuse, Santé publique, Vaccins antigrippaux, Vaccins atténués.
- Administration par voie nasale, Adolescent, Allemagne, Analyse coût-bénéfice, Années de vie ajustées sur la qualité, Enfant, Enfant d'âge préscolaire, Humains, Modèles économétriques.
Wicri :
- geographic : Allemagne.

English descriptors

KwdEn :
- Administration, Intranasal (MeSH), Adolescent (MeSH), Analgesics (administration & dosage), Analgesics (economics), Anti-Bacterial Agents (administration & dosage), Anti-Bacterial Agents (economics), Child (MeSH), Child, Preschool (MeSH), Cost-Benefit Analysis (MeSH), Germany (MeSH), Humans (MeSH), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (economics), Influenza, Human (prevention & control), Models, Econometric (MeSH), Otitis Media (economics), Otitis Media (prevention & control), Pneumonia (economics), Pneumonia (prevention & control), Public Health (economics), Quality-Adjusted Life Years (MeSH), Vaccines, Attenuated (administration & dosage), Vaccines, Attenuated (adverse effects), Vaccines, Attenuated (economics).
MESH :
- chemical , administration & dosage : Analgesics, Anti-Bacterial Agents, Influenza Vaccines, Vaccines, Attenuated.
- chemical , adverse effects : Influenza Vaccines, Vaccines, Attenuated.
- chemical , economics : Analgesics, Anti-Bacterial Agents, Influenza Vaccines, Vaccines, Attenuated.
- geographic : Germany.
- economics : Otitis Media, Pneumonia, Public Health.
- prevention & control : Influenza, Human, Otitis Media, Pneumonia.
- Administration, Intranasal, Adolescent, Child, Child, Preschool, Cost-Benefit Analysis, Humans, Models, Econometric, Quality-Adjusted Life Years.

Abstract

In 2011, intranasally administered live attenuated influenza vaccine (LAIV) was approved in the EU for prophylaxis of seasonal influenza in 2-17-year-old children. Our objective was to estimate the potential epidemiological impact and cost-effectiveness of an LAIV-based extension of the influenza vaccination programme to healthy children in Germany. An age-structured dynamic model of influenza transmission was developed and combined with a decision-tree to evaluate different vaccination strategies in the German health care system. Model inputs were based on published literature or were derived by expert consulting using the Delphi technique. Unit costs were drawn from German sources. Under base-case assumptions, annual routine vaccination of children aged 2-17 years with LAIV assuming an uptake of 50% would prevent, across all ages, 16 million cases of symptomatic influenza, over 600,000 cases of acute otitis media, nearly 130,000 cases of community-acquired pneumonia, nearly 1.7 million prescriptions of antibiotics and over 165,000 hospitalisations over 10 years. The discounted incremental cost-effectiveness ratio was 1,228 per quality-adjusted life year gained from a broad third-party payer perspective (including reimbursed direct costs and specific transfer payments), when compared with the current strategy of vaccinating primarily risk groups with the conventional trivalent inactivated vaccine. Inclusion of patient co-payments and indirect costs in terms of productivity losses resulted in discounted 10-year cost savings of 3.4 billion. In conclusion, adopting universal influenza immunisation of healthy children and adolescents would lead to a substantial reduction in influenza-associated disease at a reasonable cost to the German statutory health insurance system. On the basis of the epidemiological and health economic simulation results, a recommendation of introducing annual routine influenza vaccination of children 2-17 years of age might be taken into consideration.

DOI: 10.1007/s10198-014-0586-4
PubMed: 24859492
PubMed Central: PMC4435640

Affiliations:

Allemagne

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000165
to stream Main, to step Curation: 000165

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.</title>
<author><name sortKey="Damm, Oliver" sort="Damm, Oliver" uniqKey="Damm O" first="Oliver" last="Damm">Oliver Damm</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Health Economics and Health Care Management, Bielefeld School of Public Health, Bielefeld University, Universitätsstraße 25, 33615, Bielefeld, Germany, oliver.damm@uni-bielefeld.de.</nlm:affiliation>
<country wicri:rule="url">Allemagne</country>
<wicri:regionArea>Department of Health Economics and Health Care Management, Bielefeld School of Public Health, Bielefeld University, Universitätsstraße 25, 33615, Bielefeld, Germany</wicri:regionArea>
<wicri:noRegion>Germany</wicri:noRegion>
<wicri:noRegion>Germany</wicri:noRegion>
<wicri:noRegion>Germany</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Eichner, Martin" sort="Eichner, Martin" uniqKey="Eichner M" first="Martin" last="Eichner">Martin Eichner</name>
</author>
<author><name sortKey="Rose, Markus Andreas" sort="Rose, Markus Andreas" uniqKey="Rose M" first="Markus Andreas" last="Rose">Markus Andreas Rose</name>
</author>
<author><name sortKey="Knuf, Markus" sort="Knuf, Markus" uniqKey="Knuf M" first="Markus" last="Knuf">Markus Knuf</name>
</author>
<author><name sortKey="Wutzler, Peter" sort="Wutzler, Peter" uniqKey="Wutzler P" first="Peter" last="Wutzler">Peter Wutzler</name>
</author>
<author><name sortKey="Liese, Johannes Gunter" sort="Liese, Johannes Gunter" uniqKey="Liese J" first="Johannes Günter" last="Liese">Johannes Günter Liese</name>
</author>
<author><name sortKey="Kruger, Hagen" sort="Kruger, Hagen" uniqKey="Kruger H" first="Hagen" last="Krüger">Hagen Krüger</name>
</author>
<author><name sortKey="Greiner, Wolfgang" sort="Greiner, Wolfgang" uniqKey="Greiner W" first="Wolfgang" last="Greiner">Wolfgang Greiner</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:24859492</idno>
<idno type="pmid">24859492</idno>
<idno type="doi">10.1007/s10198-014-0586-4</idno>
<idno type="pmc">PMC4435640</idno>
<idno type="wicri:Area/Main/Corpus">000165</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000165</idno>
<idno type="wicri:Area/Main/Curation">000165</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000165</idno>
<idno type="wicri:Area/Main/Exploration">000165</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.</title>
<author><name sortKey="Damm, Oliver" sort="Damm, Oliver" uniqKey="Damm O" first="Oliver" last="Damm">Oliver Damm</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Health Economics and Health Care Management, Bielefeld School of Public Health, Bielefeld University, Universitätsstraße 25, 33615, Bielefeld, Germany, oliver.damm@uni-bielefeld.de.</nlm:affiliation>
<country wicri:rule="url">Allemagne</country>
<wicri:regionArea>Department of Health Economics and Health Care Management, Bielefeld School of Public Health, Bielefeld University, Universitätsstraße 25, 33615, Bielefeld, Germany</wicri:regionArea>
<wicri:noRegion>Germany</wicri:noRegion>
<wicri:noRegion>Germany</wicri:noRegion>
<wicri:noRegion>Germany</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Eichner, Martin" sort="Eichner, Martin" uniqKey="Eichner M" first="Martin" last="Eichner">Martin Eichner</name>
</author>
<author><name sortKey="Rose, Markus Andreas" sort="Rose, Markus Andreas" uniqKey="Rose M" first="Markus Andreas" last="Rose">Markus Andreas Rose</name>
</author>
<author><name sortKey="Knuf, Markus" sort="Knuf, Markus" uniqKey="Knuf M" first="Markus" last="Knuf">Markus Knuf</name>
</author>
<author><name sortKey="Wutzler, Peter" sort="Wutzler, Peter" uniqKey="Wutzler P" first="Peter" last="Wutzler">Peter Wutzler</name>
</author>
<author><name sortKey="Liese, Johannes Gunter" sort="Liese, Johannes Gunter" uniqKey="Liese J" first="Johannes Günter" last="Liese">Johannes Günter Liese</name>
</author>
<author><name sortKey="Kruger, Hagen" sort="Kruger, Hagen" uniqKey="Kruger H" first="Hagen" last="Krüger">Hagen Krüger</name>
</author>
<author><name sortKey="Greiner, Wolfgang" sort="Greiner, Wolfgang" uniqKey="Greiner W" first="Wolfgang" last="Greiner">Wolfgang Greiner</name>
</author>
</analytic>
<series><title level="j">The European journal of health economics : HEPAC : health economics in prevention and care</title>
<idno type="eISSN">1618-7601</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal (MeSH)</term>
<term>Adolescent (MeSH)</term>
<term>Analgesics (administration & dosage)</term>
<term>Analgesics (economics)</term>
<term>Anti-Bacterial Agents (administration & dosage)</term>
<term>Anti-Bacterial Agents (economics)</term>
<term>Child (MeSH)</term>
<term>Child, Preschool (MeSH)</term>
<term>Cost-Benefit Analysis (MeSH)</term>
<term>Germany (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (adverse effects)</term>
<term>Influenza Vaccines (economics)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Models, Econometric (MeSH)</term>
<term>Otitis Media (economics)</term>
<term>Otitis Media (prevention & control)</term>
<term>Pneumonia (economics)</term>
<term>Pneumonia (prevention & control)</term>
<term>Public Health (economics)</term>
<term>Quality-Adjusted Life Years (MeSH)</term>
<term>Vaccines, Attenuated (administration & dosage)</term>
<term>Vaccines, Attenuated (adverse effects)</term>
<term>Vaccines, Attenuated (economics)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale (MeSH)</term>
<term>Adolescent (MeSH)</term>
<term>Allemagne (MeSH)</term>
<term>Analgésiques (administration et posologie)</term>
<term>Analgésiques (économie)</term>
<term>Analyse coût-bénéfice (MeSH)</term>
<term>Années de vie ajustées sur la qualité (MeSH)</term>
<term>Antibactériens (administration et posologie)</term>
<term>Antibactériens (économie)</term>
<term>Enfant (MeSH)</term>
<term>Enfant d'âge préscolaire (MeSH)</term>
<term>Grippe humaine (prévention et contrôle)</term>
<term>Humains (MeSH)</term>
<term>Modèles économétriques (MeSH)</term>
<term>Otite moyenne (prévention et contrôle)</term>
<term>Otite moyenne (économie)</term>
<term>Pneumopathie infectieuse (prévention et contrôle)</term>
<term>Pneumopathie infectieuse (économie)</term>
<term>Santé publique (économie)</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (effets indésirables)</term>
<term>Vaccins antigrippaux (économie)</term>
<term>Vaccins atténués (administration et posologie)</term>
<term>Vaccins atténués (effets indésirables)</term>
<term>Vaccins atténués (économie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Analgesics</term>
<term>Anti-Bacterial Agents</term>
<term>Influenza Vaccines</term>
<term>Vaccines, Attenuated</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Attenuated</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Analgesics</term>
<term>Anti-Bacterial Agents</term>
<term>Influenza Vaccines</term>
<term>Vaccines, Attenuated</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Analgésiques</term>
<term>Antibactériens</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Otitis Media</term>
<term>Pneumonia</term>
<term>Public Health</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
<term>Otitis Media</term>
<term>Pneumonia</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term>
<term>Otite moyenne</term>
<term>Pneumopathie infectieuse</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Analgésiques</term>
<term>Antibactériens</term>
<term>Otite moyenne</term>
<term>Pneumopathie infectieuse</term>
<term>Santé publique</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term>
<term>Adolescent</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Cost-Benefit Analysis</term>
<term>Humans</term>
<term>Models, Econometric</term>
<term>Quality-Adjusted Life Years</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term>
<term>Adolescent</term>
<term>Allemagne</term>
<term>Analyse coût-bénéfice</term>
<term>Années de vie ajustées sur la qualité</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Humains</term>
<term>Modèles économétriques</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In 2011, intranasally administered live attenuated influenza vaccine (LAIV) was approved in the EU for prophylaxis of seasonal influenza in 2-17-year-old children. Our objective was to estimate the potential epidemiological impact and cost-effectiveness of an LAIV-based extension of the influenza vaccination programme to healthy children in Germany. An age-structured dynamic model of influenza transmission was developed and combined with a decision-tree to evaluate different vaccination strategies in the German health care system. Model inputs were based on published literature or were derived by expert consulting using the Delphi technique. Unit costs were drawn from German sources. Under base-case assumptions, annual routine vaccination of children aged 2-17 years with LAIV assuming an uptake of 50% would prevent, across all ages, 16 million cases of symptomatic influenza, over 600,000 cases of acute otitis media, nearly 130,000 cases of community-acquired pneumonia, nearly 1.7 million prescriptions of antibiotics and over 165,000 hospitalisations over 10 years. The discounted incremental cost-effectiveness ratio was  1,228 per quality-adjusted life year gained from a broad third-party payer perspective (including reimbursed direct costs and specific transfer payments), when compared with the current strategy of vaccinating primarily risk groups with the conventional trivalent inactivated vaccine. Inclusion of patient co-payments and indirect costs in terms of productivity losses resulted in discounted 10-year cost savings of  3.4 billion. In conclusion, adopting universal influenza immunisation of healthy children and adolescents would lead to a substantial reduction in influenza-associated disease at a reasonable cost to the German statutory health insurance system. On the basis of the epidemiological and health economic simulation results, a recommendation of introducing annual routine influenza vaccination of children 2-17 years of age might be taken into consideration.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24859492</PMID>
<DateCompleted><Year>2016</Year>
<Month>02</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1618-7601</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>16</Volume>
<Issue>5</Issue>
<PubDate><Year>2015</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>The European journal of health economics : HEPAC : health economics in prevention and care</Title>
<ISOAbbreviation>Eur J Health Econ</ISOAbbreviation>
</Journal>
<ArticleTitle>Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.</ArticleTitle>
<Pagination><MedlinePgn>471-88</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s10198-014-0586-4</ELocationID>
<Abstract><AbstractText>In 2011, intranasally administered live attenuated influenza vaccine (LAIV) was approved in the EU for prophylaxis of seasonal influenza in 2-17-year-old children. Our objective was to estimate the potential epidemiological impact and cost-effectiveness of an LAIV-based extension of the influenza vaccination programme to healthy children in Germany. An age-structured dynamic model of influenza transmission was developed and combined with a decision-tree to evaluate different vaccination strategies in the German health care system. Model inputs were based on published literature or were derived by expert consulting using the Delphi technique. Unit costs were drawn from German sources. Under base-case assumptions, annual routine vaccination of children aged 2-17 years with LAIV assuming an uptake of 50% would prevent, across all ages, 16 million cases of symptomatic influenza, over 600,000 cases of acute otitis media, nearly 130,000 cases of community-acquired pneumonia, nearly 1.7 million prescriptions of antibiotics and over 165,000 hospitalisations over 10 years. The discounted incremental cost-effectiveness ratio was  1,228 per quality-adjusted life year gained from a broad third-party payer perspective (including reimbursed direct costs and specific transfer payments), when compared with the current strategy of vaccinating primarily risk groups with the conventional trivalent inactivated vaccine. Inclusion of patient co-payments and indirect costs in terms of productivity losses resulted in discounted 10-year cost savings of  3.4 billion. In conclusion, adopting universal influenza immunisation of healthy children and adolescents would lead to a substantial reduction in influenza-associated disease at a reasonable cost to the German statutory health insurance system. On the basis of the epidemiological and health economic simulation results, a recommendation of introducing annual routine influenza vaccination of children 2-17 years of age might be taken into consideration.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Damm</LastName>
<ForeName>Oliver</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Department of Health Economics and Health Care Management, Bielefeld School of Public Health, Bielefeld University, Universitätsstraße 25, 33615, Bielefeld, Germany, oliver.damm@uni-bielefeld.de.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Eichner</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Rose</LastName>
<ForeName>Markus Andreas</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Knuf</LastName>
<ForeName>Markus</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wutzler</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liese</LastName>
<ForeName>Johannes Günter</ForeName>
<Initials>JG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Krüger</LastName>
<ForeName>Hagen</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Greiner</LastName>
<ForeName>Wolfgang</ForeName>
<Initials>W</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>05</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Eur J Health Econ</MedlineTA>
<NlmUniqueID>101134867</NlmUniqueID>
<ISSNLinking>1618-7598</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000700">Analgesics</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017059" MajorTopicYN="N">Models, Econometric</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010033" MajorTopicYN="N">Otitis Media</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011014" MajorTopicYN="N">Pneumonia</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year>
<Month>12</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>03</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>5</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>5</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>2</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24859492</ArticleId>
<ArticleId IdType="doi">10.1007/s10198-014-0586-4</ArticleId>
<ArticleId IdType="pmc">PMC4435640</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Dtsch Med Wochenschr. 2010 Sep;135(37):1792-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20824600</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Jun 5;24(23):4934-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16678945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gesundheitswesen. 2008 Jun;70(6):e1-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18661452</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Fam Pract. 2001 Dec;18(6):629-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11739352</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Jan 20;30(5):886-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22155144</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Geriatr Soc. 2011 Feb;59(2):327-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21275932</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2011 Oct 13;365(15):1406-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21995388</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1993 Oct;168(4):881-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8376833</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2011 Dec 3;378(9807):1917-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22078723</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2001 Mar 22;344(12):889-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11259722</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Ther. 2009 Oct;31(10):2140-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19922885</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2010;15(44). pii: 19700</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21087586</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dtsch Med Wochenschr. 2006 Mar 3;131(9):453-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16493571</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 2000 Nov;106(5):973-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11061762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Health Econ. 1995 Jun;14(2):171-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10154656</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2010 Dec 1;202(11):1626-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21028955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2012 Jan;12(1):36-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22032844</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Sep 24;361(13):1260-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19776407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Jun 10;29(26):4334-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21510993</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Jun 2;26(23):2841-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18462851</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin. 2007 Jan-Feb;3(1):14-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17245134</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med. 2008 Apr;121(4):258-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18374680</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thorax. 2009 Dec;64(12):1062-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19454409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Jul 12;28(31):4913-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20576536</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2005 Jan 26;23(10):1284-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15652671</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 2006 Dec;118(6):2409-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17142526</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2009 Jun;58(6):446-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19446340</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2010;(2):CD004876</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20166072</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Infect. 2008 Jun;136(6):852-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17634159</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Klin (Munich). 2001 Feb 15;96(2):63-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11253284</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Oct 6;29(43):7524-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21820476</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2011 Nov;5(6):389-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21668683</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Jun 28;25(27):5086-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17544181</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Health Syst Pharm. 2009 Mar 1;66(5):469-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19233995</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2008;26(11):911-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18850761</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Public Health. 2008;8:272</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18673545</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2008;(2):CD004879</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18425905</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2010;10:168</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20546586</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2006 Oct;12(10):1548-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17176570</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Epidemiol. 2008 Apr 1;167(7):775-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18230677</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Respir Med. 2000 Jun;94(6):556-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10921759</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Microbiol Infect Dis. 2000 Nov;19(11):834-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11152308</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2014;14:40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24450996</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2012;8:CD004879</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22895945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Oct 6;29(43):7554-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21820477</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoeconomics. 2000 Jun;17(6):611-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10977398</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2001 Jul 20;19(30):4204-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11457546</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Sep 26;26(41):5321-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18647634</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2004 Oct 15;190(8):1369-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15378427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Feb 11;27(7):1101-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19095024</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Infect. 2006 Feb;134(1):71-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16316494</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Infect Dis J. 2007 Jul;26(7):619-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17596805</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Infect Dis J. 2008 Aug;27(8):744-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18600188</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2010 Mar 10;303(10):943-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20215608</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2008 Mar 25;5(3):e74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18366252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2005 Jan 11;23(8):1004-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15620473</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pediatr (Phila). 2011 Nov;50(11):1068-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21098532</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Health Policy. 2008 May;86(2-3):142-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18054109</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Psychother Psychosom Med Psychol. 2006 Feb;56(2):42-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16453241</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Infect Dis J. 2010 Sep;29(9):806-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20458256</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 May 8;24(19):4222-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16423432</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Themes Epidemiol. 2005 Jun 21;2:6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15969758</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 2006 Nov;118(5):2032-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17079576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 May 15;24(20):4378-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16574281</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2012 Mar;8(3):312-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22330959</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 1999 Jun;103(6):e73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10353970</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Klin Padiatr. 2002 Nov-Dec;214(6):334-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12424681</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Feb 20;24(8):1047-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16298026</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2006 Jul 6;355(1):31-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16822994</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2011 May;37(5):1151-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20817703</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2009;338:b2242</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19549995</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Dis Child. 2004 Nov;89(11):1002-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15499051</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2011 May;62(5):379-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21414357</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
</country>
</list>
<tree><noCountry><name sortKey="Eichner, Martin" sort="Eichner, Martin" uniqKey="Eichner M" first="Martin" last="Eichner">Martin Eichner</name>
<name sortKey="Greiner, Wolfgang" sort="Greiner, Wolfgang" uniqKey="Greiner W" first="Wolfgang" last="Greiner">Wolfgang Greiner</name>
<name sortKey="Knuf, Markus" sort="Knuf, Markus" uniqKey="Knuf M" first="Markus" last="Knuf">Markus Knuf</name>
<name sortKey="Kruger, Hagen" sort="Kruger, Hagen" uniqKey="Kruger H" first="Hagen" last="Krüger">Hagen Krüger</name>
<name sortKey="Liese, Johannes Gunter" sort="Liese, Johannes Gunter" uniqKey="Liese J" first="Johannes Günter" last="Liese">Johannes Günter Liese</name>
<name sortKey="Rose, Markus Andreas" sort="Rose, Markus Andreas" uniqKey="Rose M" first="Markus Andreas" last="Rose">Markus Andreas Rose</name>
<name sortKey="Wutzler, Peter" sort="Wutzler, Peter" uniqKey="Wutzler P" first="Peter" last="Wutzler">Peter Wutzler</name>
</noCountry>
<country name="Allemagne"><noRegion><name sortKey="Damm, Oliver" sort="Damm, Oliver" uniqKey="Damm O" first="Oliver" last="Damm">Oliver Damm</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000131 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000131 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeAllemagneV4
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:24859492
   |texte=   Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:24859492" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeAllemagneV4

This area was generated with Dilib version V0.6.35.
Data generation: Mon Aug 10 17:53:30 2020. Site generation: Sat Mar 27 17:40:37 2021

	Serveur d'exploration sur la grippe en Allemagne
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la grippe en Allemagne

Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.

Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki